REPORT AND FINANCIAL STATEMENTS SEPTEMBER 30, 2024



INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Lupus Ontario

Qualified Opinion

We have audited the financial statements of Lupus Ontario, which comprise the statement of financial position as at September 30, 2024, and the statements of operations and unrestricted fund balance, internally restricted fund balance, emergency medication assistance fund balance and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the effects of the matter described in the Basis for Qualified Opinion section of our report, the accompanying financial statements present fairly, in all material respects, the financial position of Lupus Ontario as at September 30, 2024, and its results of operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for Qualified Opinion

In common with many not-for-profit organizations, Lupus Ontario derives revenues from donations and other activities, the completeness of which is not susceptible to satisfactory audit verification. Accordingly, our verification of these revenues was limited to the amounts recorded in the records of Lupus Ontario and we were not able to determine whether any adjustments might be necessary to fees and other revenues, assets and net assets.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of Lupus Ontario in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing Lupus Ontario's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate Lupus Ontario or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing Lupus Ontario's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to
 fraud or error, design and perform audit procedures responsive to those risks, and obtain audit
 evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not
 detecting a material misstatement resulting from fraud is higher than for one resulting from error,
 as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the
 override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Lupus Ontario's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on Lupus Ontario's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause Lupus Ontario to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Gilmore + Company US

(Incorporated under The Business Corporations Act - Ontario)

_____ Director

STATEMENT OF FINANCIAL POSITION

As at September 30, 2024

	2024	2023
ASSETS		
Current		
Cash	\$ 46,163	\$ 51,379
Short-term investment	1,648,869	1,422,748
Accounts receivable	1,782	34,600
Government remittances receivable	8,436	119
Prepaid expenses	6,962	1,965
	\$ 1,712,212	\$ 1,510,811
LIABILITIES		
Current		
Accounts payable and accrued liabilities	\$ 59,671	\$ 89,449
Long-term debt (Note 3)	-	40,000
	59,671	129,449
FUND BALANCES		
Deferred contributions (Note 4)	146,265	108,638
Unrestricted fund balance (page 2)	195,954	(38,093)
Internally restricted fund balance (page 3)	1,308,817	1,308,817
Emergency medication assistance fund balance (page 4)	1,505	2,000
	1,652,541	1,381,362
	\$ 1,712,212	\$ 1,510,811
On behalf of the Board		
Director		

Page 1

STATEMENT OF OPERATIONS AND UNRESTRICTED FUND BALANCE

For the year ended September 30, 2024

- Tor the year chieu septemoer 50, 2021		2024		2023	
Receipts					
Investment and interest income	\$	327,827	\$	81,977	
Walk for Lupus		122,590		157,263	
Bequests		74,172		10,455	
Research donations and grants		67,698		163,964	
Lupus Ontario Spring Gala		36,658		-	
Deferred contributions recognized as revenue		26,000		289	
Charitable donations		15,557		23,353	
Lupus Ontario silent auction		15,427		22,955	
Ottawa Door to Door		9,595		8,596	
90's Dance		-		8,178	
Third party events		5,309		7,189	
Memorial donations		5,295		11,616	
Corporate grants		-		10,000	
		706,128		505,835	
Expenses					
Administration		26,529		31,422	
Fundraising		120,754		110,111	
Public awareness		86,570		54,962	
Research funding and clinic support		141,222		168,385	
Support and education programs		74,015		66,797	
Volunteer support		22,991		27,295	
		472,081		458,972	
Excess of receipts over expenses		234,047		46,863	
Unrestricted fund balance, beginning of year		(38,093)		(82,956)	
		195,954		(36,093)	
Transfer to emergency medication assistance fund		-		(2,000)	
Unrestricted fund balance, end of year	\$	195,954	\$	(38,093)	

STATEMENT OF INTERNALLY RESTRICTED FUND BALANCE

For the year ended September 30, 2024

	2024	2023
Internally restricted fund balance, beginning of vear	\$ 1,308,817	\$ 1,308,817
Internally restricted fund balance, end of year	\$ 1,308,817	\$ 1,308,817

STATEMENT OF EMERGENCY MEDICATION ASSISTANCE FUND BALANCE For the year ended September 30, 2024

	2024		2023	
Emergency medication assistance fund balance, beginning of year	\$	2,000	\$	
Receipts		-		
Expenses Medications		495		-
Deficiency of receipts over expenses		(495)		-
Transfer from (to) unrestricted fund balance		-		2,000
Emergency medication assistance fund balance, end of year	\$	1,505	\$	2,000

STATEMENT OF CASH FLOWS

For the year ended September 30, 2024

	2024	2023
Cash used in:		
Operating activities		
Excess of receipts over expenses - unrestricted fund Deficiency of receipts over expenses - Emergency	\$ 234,047	\$ 46,863
medication assistance fund	(495)	
	233,552	46,863
Net changes in non-cash working capital amounts:		
Accounts receivable	32,818	(34,600)
Government remittances receivable	(8,317)	-
Prepaid expenses	(4,997)	4,227
Accounts payable and accrued liabilities	(29,778)	483
Government remittances payable Deferred contributions	- 37,627	(346) 29,085
Deferred contributions	37,027	29,000
	260,905	45,712
Financing activity		
Proceeds of long-term debt	(40,000)	
Investing activity		
Short-term investment	(226,121)	(63,291)
Short term investment	(==0)1=1)	(00)2)1)
Net decrease in cash during the year	(5,216)	(17,579)
Cash, beginning of the year	51,379	68,958
Cash, end of the year	\$ 46,163	\$ 51,379

September 30, 2024

Organization and purpose

Lupus Ontario was incorporated without share capital by letters patent under the Ontario Corporations Act.

Lupus Ontario raises money to provide support, education, public awareness, advocacy and to fund research. Lupus Ontario offers both support and education to those suffering from Lupus and their families and friends. Research contributions are used to fund various accredited Ontario Lupus Clinics, the Lupus Ontario Anne Matheson Biobank and the Geoff Carr Lupus Research Fellowship which enables a Rheumatology resident to extend their study for a year at an accredited Ontario Lupus Clinic and to perform lupus research. Money is raised by donations, memorials, bequests and special events.

Lupus Ontario is a registered charitable organization within the meaning of the Income Tax Act (Canada) and is exempt from income taxes.

1. Summary of significant accounting policies

These financial statements have been prepared in accordance with Canadian accounting standards for not-for-profit organizations and include the following significant accounting policies:

Revenue recognition

Lupus Ontario follows the deferral method in accounting for revenue, where all contributions and event revenue are recorded when received. Restricted contributions are recorded as revenue in the period in which the related expenses are incurred. Interest and investment income is recorded on the accrual basis, as earned. Endowment contributions are recognized as direct increases in net assets in the year.

Short-term investments

Short-term investments in equity instruments that are quoted in an active market are measured at fair value. Changes in fair value are recognized in net income or deferred contributions as applicable, in the period incurred. Transaction costs that are directly attributable to the acquisition of these investments are recognized in net income in the period incurred.

September 30, 2024

1. Summary of significant accounting policies (continued)

Endowment/Restricted Funds

Certain major donations or bequests received are restricted as per the donor's request or the organization's Board of Directors. Donor restricted amounts are allocated to deferred contributions. Investment income earned on donor restricted funds is added to amounts held in deferred contributions. Amounts internally restricted for specific purposes by the Board of Directors are segregated and presented separately from Lupus Ontario's unrestricted fund balance. These funds are maintained separately and invested in fixed income and equity type financial instruments as set out in the Investment Policy guidelines approved by the Board of Directors. The investment income generated on the internally restricted capital may be used to support activities of the organization as approved by the Board of Directors.

Government assistance

Government grants and subsidies, which include the forgivable portion of government loans, are recognized in earnings in the period in which there is reasonable assurance that Lupus Ontario has complied with the conditions attaching to such government grants and subsidies.

Use of estimates

The preparation of financial statements in accordance with Canadian accounting standards for not-for-profit organizations requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Such estimates include allowances for doubtful accounts. Actual results could differ from those estimates. On an ongoing basis, management reviews its estimates, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.

Donated services/ services in kind

The fair value of donated services and services in kind, where determinable, are not reflected in these statements.

September 30, 2024

1. Summary of significant accounting policies (continued)

Financial instruments

Lupus Ontario initially measures its financial assets and liabilities at fair value. Lupus Ontario subsequently measures all its financial assets and financial liabilities at amortized cost, except for investments in equity instruments that are quoted in an active market, which are measured at fair value. Changes in fair value are recognized in net income or deferred contributions as applicable.

2. Financial instruments

The significant financial risks to which Lupus Ontario is exposed are as follows:

Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Lupus Ontario's investments in publicly traded securities expose Lupus Ontario to market risk as such investments are subject to price changes in the open market. Lupus Ontario does not use derivative financial instruments to alter the effects of this risk.

Liquidity risk

Liquidity risk is the risk that Lupus Ontario will encounter difficulty in meeting obligations associated with financial liabilities. Lupus Ontario is exposed to liquidity risk arising primarily from its accounts payable and accrued liabilities. Lupus Ontario expects to meet its obligations as they come due by generating sufficient cash flow from operations.

Credit risk

Credit risk arises from the potential that a counter party will fail to perform its obligations. Lupus Ontario is exposed to credit risk from pledges. Lupus Ontario monitors the credit risk and credit rating of individuals and entities that have made pledges to Lupus Ontario and maintains an allowance where collectibility is doubtful.

September 30, 2024

3. Long-term debt

Canada Emergency Business Account (CEBA), a Government of Canada loan of \$60,000 (2023 - \$60,000), bears interest at 0% per annum, repayable on or before January 18, 2024. A repayment of 67% (2023 - 67%) of the loan on or before January 18, 2024 will result in 33% (2023 - 33%) of the loan being forgiven. The forgivable portion was recognized as income in the 2021 fiscal year. The loan was repaid on January 1, 2024.

4. Deferred contributions

Deferred contributions represent monies designated for the Melissa Salsburg Fund, the Order Eastern Star, the Janet Calderone trust, the Gotkin Family fund to be used for operations, Geoff Carr fellowship, the Mary Frances Perpick fund to be used in Sudbury, website redesign, Honey Agar Fellowship and the Mississauga Legion fund to be used in Mississauga. Research contributions represent monies received and restricted for research projects and had a \$nil balance at year end.

	September 30, 2023	Receipts	Revenue Recognized	Change in Market Value of Investments	September 30, 2024
Melissa Salsburg Fund	\$ 6,080	\$ 1,200	\$ 6,000	\$ -	\$ 1,280
Order Eastern Star	138	-	-	-	138
Janet Calderone trust	75,466	-	-	6,231	81,697
Gotkin Family	1,276		-	-	1,276
Geoff Carr fellowship	20,000	-	20,000	-	-
Mary Frances Perpick	178	-	-	-	178
Website redesign	5,000	30,000	-	-	35,000
Honey Agar Fellowship	-	26,196	-	-	26,196
Mississauga Legion	250	-	-	-	250
Daughter of Isabella	250	-	-	-	250
	\$108,638	\$ 57,396	\$ 26,000	\$ 6,231	\$ 146,265